iSpecimen (ISPC) EBITDA (2020 - 2026)

iSpecimen's EBITDA history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, EBITDA fell 53.06% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$11.4 million (down 1.01% YoY), while the FY2025 annual figure was -$10.5 million, up 16.09% from the prior year.
• EBITDA was -$2.5 million for Q1 2026 at iSpecimen, up from -$5.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.0 million in Q2 2025 to a low of -$6.0 million in Q4 2024.
• Historically, EBITDA has averaged -$2.8 million across 5 years, with a median of -$2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 150.19% in 2022, then jumped 50.35% in 2025.
• A 5-year view of EBITDA shows it stood at -$2.1 million in 2022, then slumped by 34.06% to -$2.9 million in 2023, then plunged by 110.62% to -$6.0 million in 2024, then climbed by 17.29% to -$5.0 million in 2025, then surged by 49.24% to -$2.5 million in 2026.
• The last three EBITDA figures came in at -$2.5 million (Q1 2026), -$5.0 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.